Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus

World Journal of Gastroenterology

Volumn 24, Issue 12, 2018, Pages 1353-1360

  Rupp, Christian ^a   Hippchen, Theresa ^a   Neuberger, Manuel ^a   Sauer, Peter ^a   Pfeiffenberger, Jan ^a   Stremmel, Wolfgang ^a   Gotthardt, Daniel Nils ^a   Mehrabi, Arianeb ^a   Weiss, Karl Heinz ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Direct acting antivirals; Hepatitis C virus; Liver transplantation; Recurrence; Sustained virological response

Indexed keywords

DACLATASVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IRRITABILITY; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; POSTOPERATIVE CARE; RECURRENT INFECTION; REINFECTION; RELAPSE; REVIEW; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TERTIARY CARE CENTER; THROMBOCYTOPENIA; TREATMENT DURATION; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DRUG EFFECT; END STAGE LIVER DISEASE; GENOTYPE; GERMANY; GRAFT REJECTION; HEPACIVIRUS; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; FEMALE; GENOTYPE; GERMANY; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85045040675     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v24.i12.1353     Document Type: Review

References (35)

1. Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology 2017; 152: 10901099.e1 [PMID: 28088461 DOI: 10.1053/ j.gastro.2017.01.003]
2. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110113 [PMID: 10390360]
3. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11: 482496 [PMID: 23748342 DOI: 10.1038/nrmicro3046]
4. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, LerouxRoels G, Rice CM. Cell culturegrown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 38053809 [PMID: 16484368 DOI: 10.1073/ pnas.0511218103]
5. Weiler N, Zeuzem S, Welker MW. Concise review: Interferonfree treatment of hepatitis C virusassociated cirrhosis and liver graft infection. World J Gastroenterol 2016; 22: 90449056 [PMID: 27895394 DOI: 10.3748/wjg.v22.i41.9044]
6. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, PilotMatias T, Vilchez RA, Forns X. An interferonfree antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 23752382 [PMID: 25386767 DOI: 10.1056/ NEJMoa1408921]
7. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 16011605 [PMID: 23593993 DOI: 10.1111/ajt.12209]
8. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, BrandtSarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londoño MC, Habersetzer F. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 14851494 [PMID: 25557906 DOI: 10.1002/hep.27681]
9. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, Gordon F, O‘Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an openlabel study. Gastroenterology 2015; 148: 100107.e1 [PMID: 25261839 DOI: 10.1053/j.gastro.2014.09.023]
10. Terrault NA, Berenguer M, Strasser SI, Gadano A, Lilly L, Samuel D, Kwo PY, Agarwal K, Curry MP, Fagiuoli S, Fung JYY, Gane E, Brown KA, Burra P, Charlton M, Pessoa MG, McCaughan GW. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation 2017; 101: 956967 [PMID: 28437388 DOI: 10.1097/TP.0000000000001704]
11. Fontana RJ, Brown RS Jr, MorenoZamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, IonescuIttu R, Emond B, Reddy KR. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 2016; 22: 446458 [PMID: 26890629 DOI: 10.1002/lt.24416]
12. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, DvorySobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108117 [PMID: 25304641 DOI: 10.1053/j.gastro.2014.10.001]
13. Herzer K, Welzel TM, Spengler U, Hinrichsen H, Klinker H, Berg T, Ferenci P, PeckRadosavljevic M, Inderson A, Zhao Y, JimenezExposito MJ, Zeuzem S. Realworld experience with daclatasvir plus sofosbuvir ± ribavirin for postliver transplant HCV recurrence and severe liver disease. Transpl Int 2017; 30: 243255 [PMID: 28012215 DOI: 10.1111/tri.12910]
14. Kwok RM, Ahn J, Schiano TD, Te HS, Potosky DR, Tierney A, Satoskar R, Robertazzi S, Rodigas C, Lee Sang M, Wiegel J, Patel N, Gripshover J, Hassan MA, Branch A, Smith CI. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl 2016; 22: 15361543 [PMID: 27543748 DOI: 10.1002/lt.24614]
15. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, PeckRadosavljevic M, Zhao Y, JimenezExposito MJ, Zeuzem S. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a realworld cohort. Gut 2016; 65: 18611870 [PMID: 27605539 DOI: 10.1136/gutjnl2016312444]
16. Beinhardt S, PeckRadosavljevic M, Hofer H, Ferenci P. Interferonfree antiviral treatment of chronic hepatitis C in the transplant setting. Transpl Int 2015; 28: 10111024 [PMID: 25864369 DOI: 10.1111/tri.12577]
17. Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, Garcia G, Lutchman G, Kumari R, Nguyen MH. Realworld experience with interferonfree, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore) 2017; 96: e6128 [PMID: 28178174 DOI: 10.1097/MD.0000000000006128]
18. Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L. Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol 2015; 21: 44474456 [PMID: 25914454 DOI: 10.3748/wjg.v21.i15.4447]
19. Coilly A, Roche B, DuclosVallée JC, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol 2016; 1: 165172 [PMID: 28404073 DOI: 10.1016/S24681253(16)300085]
20. Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, Chung RT, Chhatwal J. Cost Effectiveness of Pre vs PostLiver Transplant Hepatitis C Treatment With DirectActing Antivirals. Clin Gastroenterol Hepatol 2018; 16: 115122.e10 [PMID: 28634131 DOI: 10.1016/j.cgh.2017.06.024]
21. Levitsky J, Verna EC, O‘Leary JG, Bzowej NH, Moonka DK, Hyland RH, Arterburn S, DvorySobol H, Brainard DM, McHutchison JG, Terrault NA. Perioperative LedipasvirSofosbuvir for HCV in LiverTransplant Recipients. N Engl J Med 2016; 375: 21062108 [PMID: 27959735 DOI: 10.1056/NEJMc1611829]
22. Younossi ZM, Stepanova M, Charlton M, Curry MP, O‘Leary JG, Brown RS, Hunt S. Patientreported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virusrelated decompensated cirrhosis: an exploratory analysis from the randomised, openlabel ASTRAL4 phase 3 trial. Lancet Gastroenterol Hepatol 2016; 1: 122132 [PMID: 28404069 DOI: 10.1016/S24681253(16)300097]
23. Ferenci P. Treatment of hepatitis C in difficulttotreat patients. Nat Rev Gastroenterol Hepatol 2015; 12: 284292 [PMID: 25895822 DOI: 10.1038/nrgastro.2015.53]
24. Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, Sulkowski MS, O‘Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and efficacy of current directacting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCVTARGET study. Hepatology 2017; 66: 10901101 [PMID: 28504842 DOI: 10.1002/hep.29258]
25. Vukotic R, Conti F, Fagiuoli S, Morelli MC, Pasulo L, Colpani M, Foschi FG, Berardi S, Pianta P, Mangano M, Donato MF, Malinverno F, Monico S, Tamè M, Mazzella G, Belli LS, Viganò R, Carrai P, Burra P, Russo FP, Lenci I, Toniutto P, Merli M, Loiacono L, Iemmolo R, Degli Antoni AM, Romano A, Picciotto A, Rendina M, Andreone P; AISFSOFOLT Study group. Longterm outcomes of direct acting antivirals in posttransplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. J Viral Hepat 2017; 24: 858864 [PMID: 28370880 DOI: 10.1111/jvh.12712]
26. Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol 2017; 67: 585602 [PMID: 28323126 DOI: 10.1016/j.jhep.2017.03.006]
27. Ferenci P, Kozbial K, Mandorfer M, Hofer H. HCV targeting of patients with cirrhosis. J Hepatol 2015; 63: 10151022 [PMID: 26100497 DOI: 10.1016/j.jhep.2015.06.003]
28. Pillai AA, Maheshwari R, Vora R, Norvell JP, Ford R, Parekh S, Cheng N, Patel A, Young N, Spivey JR, Mgbemena O, Wedd JP. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther 2017; 45: 14271432 [PMID: 28382751 DOI: 10.1111/ apt.14059]
29. Habib S, Meister E, Habib S, Murakami T, Walker C, Rana A, Shaikh OS. Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment. Gastroenterology Res 2015; 8: 237246 [PMID: 27785303 DOI: 10.14740/gr686w]
30. Young J, Weis N, Hofer H, Irving W, Weiland O, Giostra E, Pascasio JM, Castells L, Prieto M, Postema R, Lefevre C, Evans D, Bucher HC, Calleja JL. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. BMC Infect Dis 2017; 17: 45 [PMID: 28061762 DOI: 10.1186/s128790162106x]
31. Vinaixa C, Strasser SI, Berenguer M. Disease Reversibility in Patients With PostHepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review. Transplantation 2017; 101: 916923 [PMID: 28060241 DOI: 10.1097/TP.0000000000001633]
32. Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Rugge M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virusinfected patients treated with directacting antivirals. Liver Transpl 2017; 23: 11031112 [PMID: 28544587 DOI: 10.1002/lt.24790]
33. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia HCV (RESISTHCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with directacting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017; 46: 688695 [PMID: 28791711 DOI: 10.1111/apt.14256]
34. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, ElSerag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With DirectActing Antiviral Agents. Gastroenterology 2017; 153: 9961005.e1 [PMID: 28642197 DOI: 10.1053/ j.gastro.2017.06.012]
35. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017; 67: 3239 [PMID: 28267622 DOI: 10.1016/j.jhep.2017.02.027]